These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 12236347)

  • 21. Prediction of ligand binding affinity and orientation of xenoestrogens to the estrogen receptor by molecular dynamics simulations and the linear interaction energy method.
    van Lipzig MM; ter Laak AM; Jongejan A; Vermeulen NP; Wamelink M; Geerke D; Meerman JH
    J Med Chem; 2004 Feb; 47(4):1018-30. PubMed ID: 14761204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Donor-acceptor tetrahydrochrysenes, inherently fluorescent, high-affinity ligands for the estrogen receptor: binding and fluorescence characteristics and fluorometric assay of receptor.
    Hwang KJ; Carlson KE; Anstead GM; Katzenellenbogen JA
    Biochemistry; 1992 Nov; 31(46):11536-45. PubMed ID: 1445887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel method for evaluation of chemicals based on ligand-dependent recruitment of GFP labeled coactivator to estrogen receptor displayed on bacterial magnetic particles.
    Yoshino T; Kaji C; Nakai M; Saito F; Takeyama H; Matsunaga T
    Anal Chim Acta; 2008 Sep; 626(1):71-7. PubMed ID: 18761123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A model for the effect of estrogen antagonists on cooperative estradiol binding.
    Porrelli RN; Munson PJ; Rodbard D
    J Recept Res; 1993; 13(7):1055-81. PubMed ID: 8366504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential interactions of estrogens and antiestrogens at the 17 beta-hydroxyl or counterpart hydroxyl with histidine 524 of the human estrogen receptor alpha.
    Aliau S; Mattras H; Richard E; Bonnafous JC; Borgna JL
    Biochemistry; 2002 Jun; 41(25):7979-88. PubMed ID: 12069588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor.
    Gee AC; Carlson KE; Martini PG; Katzenellenbogen BS; Katzenellenbogen JA
    Mol Endocrinol; 1999 Nov; 13(11):1912-23. PubMed ID: 10551784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multiplexed screening method for agonists and antagonists of the estrogen receptor protein.
    Li Z; Yan M; Li Z; Vuki M; Wu D; Liu F; Zhong W; Zhang L; Xu D
    Anal Bioanal Chem; 2012 May; 403(5):1373-84. PubMed ID: 22453607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a stable dual cell-line GFP expression system to study estrogenic endocrine disruptors.
    Xu H; Kraus WL; Shuler ML
    Biotechnol Bioeng; 2008 Dec; 101(6):1276-87. PubMed ID: 18980187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen receptor binding assay of chemicals with a surface plasmon resonance biosensor.
    Usami M; Mitsunaga K; Ohno Y
    J Steroid Biochem Mol Biol; 2002 May; 81(1):47-55. PubMed ID: 12127041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversed-phase liquid chromatography coupled on-line to estrogen receptor bioaffinity detection based on fluorescence polarization.
    Reinen J; Kool J; Vermeulen NP
    Anal Bioanal Chem; 2008 Apr; 390(8):1987-98. PubMed ID: 18236033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytofluorometric analysis for estrogen receptors using fluorescent estrogen probes.
    Kute TE; Linville C; Barrows G
    Cytometry; 1983 Sep; 4(2):132-40. PubMed ID: 6685018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and characterization of a cell line that stably expresses an estrogen-responsive luciferase reporter for the detection of estrogen receptor agonist and antagonists.
    Wilson VS; Bobseine K; Gray LE
    Toxicol Sci; 2004 Sep; 81(1):69-77. PubMed ID: 15166400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Possible heterogeneity of cytoplasmic estrogen receptors].
    Alekseeva ML; Minina LS; Novikov EA; Shchedrina RN; Fanchenko ND
    Vopr Med Khim; 1984; 30(5):62-5. PubMed ID: 6528522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Xenobiotic interaction with and alteration of channel catfish estrogen receptor.
    Nimrod AC; Benson WH
    Toxicol Appl Pharmacol; 1997 Dec; 147(2):381-90. PubMed ID: 9439733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Equilibrium binding analysis of estrogen agonists and antagonists: relation to the activation of the estrogen receptor.
    Sasson S
    Pathol Biol (Paris); 1991 Jan; 39(1):59-69. PubMed ID: 2011412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparative study on estradiol receptor assays in human breast cancer tissue.
    Mulder J; Verhaar MA
    Clin Chim Acta; 1979 Dec; 99(2):129-34. PubMed ID: 509736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A homogeneous in vitro functional assay for estrogen receptors: coactivator recruitment.
    Liu J; Knappenberger KS; Kack H; Andersson G; Nilsson E; Dartsch C; Scott CW
    Mol Endocrinol; 2003 Mar; 17(3):346-55. PubMed ID: 12554768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigation of hormone-receptor interactions by means of fluorescence labeling.
    Dandliker WB; Brawn RJ; Hsu ML; Brawn PN; Levin J; Meyers CY; Kolb VM
    Cancer Res; 1978 Nov; 38(11 Pt 2):4212-24. PubMed ID: 212190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endocrine disruptor bisphenol A strongly binds to human estrogen-related receptor gamma (ERRgamma) with high constitutive activity.
    Takayanagi S; Tokunaga T; Liu X; Okada H; Matsushima A; Shimohigashi Y
    Toxicol Lett; 2006 Dec; 167(2):95-105. PubMed ID: 17049190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A survey of endocrine disrupting chemicals (EDCs) in municipal sewage and animal waste effluents in the Waikato region of New Zealand.
    Sarmah AK; Northcott GL; Leusch FD; Tremblay LA
    Sci Total Environ; 2006 Feb; 355(1-3):135-44. PubMed ID: 16442435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.